Skip to main content

Table 3 Treatments used in the intensive care unit (ICU) in the 84 patients

From: Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort

 

N (%) or Median [IQR]

Tocilizumab

73 (86.9)

Time from initiation to ICU admission (days)

1 (− 1.5–3)

Initiated before ICU admission

53/73 (72.6)

Number of injections

2 [1–4]

Corticosteroids a

55 (65.5)

Time from initiation to ICU admission (days)

0 (0–1)

Initiated before ICU admission

41/55 (74.5)

Cumulative dose in the ICU (mg prednisone-equivalent)

2400 [1120–4750]

Tocilizumab and Corticosteroids

52 (61.9)

Granulocyte growth factors

59 (70.2)

Anti-epileptic drug prophylaxis

81 (96.4)

Intravenous fluids, mL, median within 3 days after admission

1000 [875-1000} b

Vasopressors

23 (27.4)

Duration (days)

2 [1–4]

Maximum dose (µg/kg/min)

0.3 [0.2–0.5]

Invasive mechanical ventilation

12 (14.3)

Duration (days)

4 [3–7]

Renal replacement therapy

4 (4.8)

Duration (days)

3 [1.75–8.5]

  1. ICU Intensive care unit, ICANS Immune effector cell-associated neurotoxicity syndrome, CRS Cytokine release syndrome
  2. aIndication: ICANS (40/55); Refractory CRS (15/55)
  3. bData missing in 2 patients